May 26, 2011
9:00 AM ET
|
Johnson & Johnson Pharmaceuticals Business Review
 |
Listen to webcast |
| |
Pharmaceuticals Business Review
May 26, 2011
9:00 a.m. - 3:00 p.m.
Meeting Hosts: Sheri McCoy, Vice Chairman, Executive Committee, and Pharmaceuticals Worldwide Chairmen Joaquin Duato and Paul Stoffels, M.D.
The Heldrich Hotel, New Brunswick, New Jersey
Agenda
| Topic |
Speaker |
Podcast |
| Opening Remarks |
Louise Mehrotra, Vice President, Investor Relations |
|
| Strategic Overview |
Sheri McCoy, Vice Chairman Executive Committee |
 |
| Pharmaceutical R&D Strategy |
Paul Stoffels, M.D., Worldwide Chairman, Pharmaceuticals |
|
| Neuroscience |
Husseini K. Manji, M.D., F.R.C.P.C., Global Therapeutic Area Head, Neuroscience |
|
| Break |
|
|
| Cardiovascular / Metabolism |
Martin Fitchet, M.D., Global Therapeutic Area Head, Cardiovascular & Metabolism |
|
| Morning Session Q&A Panel |
|
|
| Lunch |
|
|
| Immunology |
Susan B. Dillon, Ph.D. , Global Therapeutic Area Head, Immunology |
|
| Oncology |
William N. Hait, M.D., Ph.D., Global Therapeutic Area Head, Oncology |
|
| Infectious Diseases and Vaccines |
Johan Van Hoof, M.D., Global Therapeutic Area Head, Infectious Diseases and Vaccines |
|
| Pharmaceutical Commercial Strategy |
Joaquin Duato, Worldwide Chairman, Pharmaceuticals |
|
| Break |
|
|
| Afternoon Session Q&A Panel |
|
|
| Closing Remarks |
Sheri McCoy, Vice Chairman Executive Committee |
|
|
|
Apr 27, 2011
8:30 AM ET
|
Johnson & Johnson and Synthes Announce Definitive Merger Agreement Conference Call
Speaker(s): Louise Mehrotra, Vice President, Investor Relations, Johnson & Johnson
William C. Weldon, Chairman, Board of Directors and Chief Executive Officer, Johnson & Johnson
Hansjoerg Wyss, Founder and Chairman of the Board, Synthes
Alex Gorsky, Vice Chairman, Executive Committee, Office of the Chairman, Johnson & Johnson
Michel Orsinger, President and Chief Executive Officer, Synthes
Dominic Caruso, Vice President Finance and Chief Financial Officer, Johnson & Johnson
Mike Mahoney, Worldwide Chairman, Medical Devices & Diagnostics; Johnson & Johnson
|
Listen to webcast |
 |
Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create World's Most Innovative and Comprehensive Orthopaedics Business 17.4 KB
|
|
Podcast |
Additional Information and Where to Find It
Johnson & Johnson will file with the SEC a registration statement on Form S-4, in which a proxy statement will be included as a prospectus, and other documents in connection with the proposed acquisition of Synthes. The proxy statement/prospectus will be sent to the stockholders of Synthes. Before making any decision with respect to the proposed transaction, stockholders of Synthes are urged to read the proxy statement/prospectus and other relevant materials because these materials will contain important information about the proposed transaction. The registration statement and proxy statement/prospectus and other documents which will be filed by Johnson & Johnson with the SEC will be available free of charge at the SEC's website, www.sec.gov, or by directing a request to Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933, Attention: Investor Relations; or by directing a request to Synthes, Inc., c/o Synthes Gmbh, Glutz-Blotzheim-Strasse 3, 4500 Solothurn, Switzerland, Attention: Investor Relations. Certain executive officers and directors of Synthes have interests in the proposed transaction that may differ from the interests of stockholders generally, including benefits conferred under retention, severance and change in control arrangements and continuation of director and officer insurance and indemnification.
|
 |
Additional Information |
This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction.
(This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson and Synthes, Inc. Risks and uncertainties include, but are not limited to, the satisfaction of closing conditions for the acquisition, including receipt of regulatory approvals for the transaction, receipt of approval by the shareholders of Synthes for the transaction, and the possibility that the transaction will not be completed, or if completed, will not be completed on a timely basis; general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to Johnson & Johnson's ability to successfully integrate the products and employees of Johnson & Johnson and Synthes, as well as the ability to ensure continued performance or market growth of Synthes' products. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Synthes can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011, and Synthes' Annual Report 2010. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.synthes.com or on request from Johnson & Johnson or Synthes. Neither Johnson & Johnson nor Synthes undertakes to update any forward-looking statements as a result of new information or future events or developments.)
|
